Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
ASART-1 clinical study is a phase 1 study which carried out to establish the pharmacokinetic
equivalence and equal safety profile of BCD-055 (infliximab manufactured by JSC BIOCAD,
Russia) and Remicade when used as multiple IV infusions for the treatment of ankylosing
spondylitis.